Secukinumab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Non-radiographic Spondyloarthritis

Conditions

Non-radiographic Spondyloarthritis

Trial Timeline

Apr 29, 2016 → Mar 11, 2021

NCT ID

NCT02696031

About Secukinumab + Placebo

Secukinumab + Placebo is a phase 3 stage product being developed by Novartis for Non-radiographic Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02696031. Target conditions include Non-radiographic Spondyloarthritis.

What happened to similar drugs?

1 of 3 similar drugs in Non-radiographic Spondyloarthritis were approved

Approved (1) Terminated (0) Active (2)

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

🔄Secukinumab + PlaceboNovartisPhase 3

✅Secukinumab + Placebo + SecukinumabNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05722522	Phase 3	Terminated	Aug 10, 2023	Dec 13, 2024	Rotator Cuff Tendinopathy
NCT05758415	Phase 3	Terminated	Aug 2, 2023	Dec 11, 2024	Rotator Cuff Tendinopathy
NCT04737330	Phase 3	Terminated	Nov 29, 2021	May 16, 2023	Thyroid Eye Disease
NCT04732117	Phase 3	Completed	Jul 21, 2021	Feb 14, 2025	Non-radiographic Axial Spondyloarthritis
NCT04181762	Phase 3	Terminated	Jul 7, 2020	Sep 13, 2023	Lupus Nephritis
NCT04156620	Phase 3	Completed	Dec 11, 2019	Dec 20, 2022	Ankylosing Spondylitis
NCT03713632	Phase 3	Completed	Feb 25, 2019	Jul 19, 2022	Hidradenitis Suppurativa
NCT03713619	Phase 3	Completed	Jan 31, 2019	Jul 26, 2022	Hidradenitis Suppurativa
NCT03055494	Approved	Completed	Apr 18, 2017	Feb 26, 2019	Plaque Psoriasis
NCT02896127	Phase 3	Completed	Oct 18, 2016	Mar 19, 2019	Ankylosing Spondyloarthritis
NCT02696031	Phase 3	Completed	Apr 29, 2016	Mar 11, 2021	Non-radiographic Spondyloarthritis
NCT02599129	Phase 2	Terminated	Nov 1, 2015	Nov 1, 2016	Alopecia Areata
NCT02594098	Phase 2	Completed	Nov 1, 2015	Jan 30, 2018	Atopic Dermatitis
NCT02362789	Phase 3	Completed	Jan 4, 2015	Jul 15, 2016	Psoriasis
NCT01989468	Phase 3	Completed	Apr 10, 2014	Mar 28, 2018	Psoriatic Arthritis
NCT02044848	Phase 2	Terminated	Feb 1, 2014	Sep 1, 2014	Type 1 Diabetes Mellitus
NCT01892436	Phase 3	Completed	Sep 30, 2013	Jan 11, 2018	Psoriatic Arthritis
NCT01807520	Phase 3	Completed	Jun 20, 2013	Jan 3, 2017	Moderate to Severe Nail Psoriasis
NCT01537432	Phase 2	Completed	Jan 1, 2012	Dec 1, 2014	Psoriasis, Plaque-type Psoriasis

Competing Products

4 competing products in Non-radiographic Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47